Leukemia Research Reports

Aims & Scope

Leukemia Research Reports (LRR), a companion title to Leukemia Research, is a peer-reviewed publication devoted to the rapid publication of short, high-quality papers related to a broad scope of therapeutic areas of hematology, including hematologic malignancies and other non-malignant diseases, such as: • Hematopoetic and stem cell transplantation; • Marrow and stem cell reconstitution; • Leukemic hemopoiesis; • Leukemias, lymphomas, multiple myelomas and other hematological malignancies; • Cell based therapies and treatment for cancer and immunotherapy for hematological malignancy.

The journal aims to publish manuscripts that provide guidance to clinicians around the world to provide education on best practices and clinical research; report cutting-edge translational science related to hematological malignancies; register important observations that significantly add to previously-reported novel observations; provide compelling illustrations of important clinical principles related to the care of patients; or foment the scientific discussion from an uncommon perspective.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 1,110.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Acute myeloid leukemia in the older adults

  Citation: 52

  Authors: Antonio M., Fernando

• Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

  Citation: 25

  Authors: Kim-Hien T., Magdolna B., Julia E., Elliott F., Richard D., Brian J., Jeffrey W.

• Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)

  Citation: 24

  Authors: Prithviraj, Steven

• An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

  Citation: 24

  Authors: Stuart L., Pierre, Michael D., Emmanuel, John, Jeannine, Arnaud, Gary J., JungAh, E., Howard, Peter

• Human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients

  Citation: 15

  Authors: Sabrina, Natalia, Gonzalo, Ana Inés, Guillermo, Juan, Pablo, Pilar

• Novel therapeutic options in Acute Myeloid Leukemia

  Citation: 14

  Authors: Michael, Claudia, Jakob

• On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia

  Citation: 13

  Authors: Peng

• Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review

  Citation: 11

  Authors: Khadega A., Bandar, Rayan, Areej Al, Bader, Giamal, Hind, Mohsen, Ayman, Ahmed, Moussab

• Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation

  Citation: 11

  Authors: Shokichi, Satoshi, Chikako, Yusuke, Masahiro, Emiko, Naomi, Koutaro, Tohru, Chiaki

• Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

  Citation: 10

  Authors: Ruby, Alla, Johnson, Thomas, Steven L.